@article{chan:hal-04510216,
TITLE = {A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors},
AUTHOR = {Chan, Stephen and Schuler, Martin and Kang, Yoon-Koo and Yen, Chia-Jui and Edeline, Julien and Choo, Su Pin and Lin, Chia-Chi and Okusaka, Takuji and Weiss, Karl-Heinz and Macarulla, Teresa and Cattan, St{\'e}phane and Blanc, Jean-Frederic and Lee, Kyung-Hun and Maur, Michela and Pant, Shubham and Kudo, Masatoshi and Assenat, Eric and Zhu, Andrew and Yau, Thomas and Lim, Ho Yeong and Bruix, Jordi and Geier, Andreas and Guill{\'e}n-Ponce, Carmen and Fasolo, Angelica and Finn, Richard and Fan, Jia and Vogel, Arndt and Qin, Shukui and Riester, Markus and Katsanou, Vasiliki and Chaudhari, Monica and Kakizume, Tomoyuki and Gu, Yi and Porta, Diana Graus and Myers, Andrea and Delord, Jean-Pierre},
URL = {https://hal.science/hal-04510216},
JOURNAL = {Journal of experimental \& clinical cancer research},
PUBLISHER = {BioMed Central},
VOLUME = {41},
NUMBER = {1},
PAGES = {189},
YEAR = {2022},
MONTH = Jun, DOI = {10.1186/s13046-022-02383-5},
KEYWORDS = {Hepatocellular carcinoma ; FGFR4 ; PD‑1 ; PD‑L1 ; Immune checkpoint inhibitors ; Phase 1 ; KLB ; FGF19},
PDF = {https://hal.science/hal-04510216/file/s13046-022-02383-5.pdf},
HAL_ID = {hal-04510216},
HAL_VERSION = {v1},
}